P768: GUADECITABINE (SGI-110) VS. TREATMENT CHOICE (TC) IN RELAPSED/REFRACTORY(R/R) MYELODYSPLASTIC SYNDROME (MDS), RESULTS OF A GLOBAL, RANDOMIZED, PHASE 3 STUDY.

• G. Garcia-Manero,
• S. Bart,
• J. K. McCloskey,
• P. Fenaux,
• D. Selleslag,
• G. Reda,
• D. Valcárcel,
• V. Santini,
• J. Mayer,
• B. Xicoy,
• H. Yamaguchi,
• M. Lübbert,
• Y. Miyazaki,
• H. Keer,
• Y. Hao,
• M. Azab,
• H. Döhner

Affiliations

G. Garcia-Manero

1 The University of Texas MD Anderson Cancer Center, Houston

S. Bart

2 Fred Hutchinson Cancer Research Center, Seattle

J. K. McCloskey

3 John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, United States of America

P. Fenaux

4 Hôpital Saint Louis, Paris, France

D. Selleslag

5 Algemeen Ziekenhuis Sint-Jan Brugge-Oostende, Brugge, Belgium

G. Reda

6 Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy

D. Valcárcel

7 Hospital Universitari Vall d’Hebrón, Barcelona, Spain

V. Santini

8 MDS Unit AOU Careggi, DMSC University of Florence, Florence, Italy

J. Mayer

9 Fakultní Nemocnice Brno, Brno, Czechia

B. Xicoy

10 Institut Català d’Oncologia-Hospital Universitari Germans Trias i Pujol, Badalona, Spain

H. Yamaguchi

11 Nippon Medical School Hospital, Tokyo, Japan

M. Lübbert

12 Universitaetsklinikum Freiburg, Freiburg, Germany

Y. Miyazaki

13 Nagasaki University Hospital, Nagasaki, Japan

H. Keer

14 Astex Pharmaceuticals, Inc., Pleasanton, United States of America

Y. Hao

14 Astex Pharmaceuticals, Inc., Pleasanton, United States of America

M. Azab

14 Astex Pharmaceuticals, Inc., Pleasanton, United States of America

H. Döhner

15 Ulm University Hospital, Ulm, Germany